Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…Abstract Number: 1663 • 2015 ACR/ARHP Annual Meeting
Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor
Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining clinical efficacy and a rapid onset of action with a good safety profile…Abstract Number: 1680 • 2015 ACR/ARHP Annual Meeting
Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis
Background/Purpose: Among the 4 Janus kinase (JAK) family members, JAK1 often has a dominant role in the intracellular signaling for cytokines involved in auto-immune and…Abstract Number: 1681 • 2015 ACR/ARHP Annual Meeting
4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
Background/Purpose: Patients with active rheumatoid arthritis (RA) present low levels of lipids - total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c) and…Abstract Number: 1773 • 2015 ACR/ARHP Annual Meeting
Pan JAK Inhibitor Tofacitinib Ameliorate Autoimmunity and Nephritis in Lupus Prone Mice Via Inhibition of Interferon Signaling Pathway
Background/Purpose: We previously reported that Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway-mediated regulation of interferon (IFN) regulatory factor (IRF)-related genes may have an…Abstract Number: 1943 • 2015 ACR/ARHP Annual Meeting
Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-Type Hypersensitivity and Psoriasis
Background/Purpose: Tyk2 is a member of the JAK family kinases and is a key mediator of IL-12, IL-23, and type I interferon signaling. These cytokines…Abstract Number: 1945 • 2015 ACR/ARHP Annual Meeting
microRNA-30a Promotes the Inflammatory Response of Rheumatoid Arthritis By Regulating Th1 Cell Differentiation
Background/Purpose: In our previous study, the transcriptome profiles of CD4+T cells from 13 active RA cases and 9 healthy controls were accessed by microarrays. a…Abstract Number: 2143 • 2015 ACR/ARHP Annual Meeting
A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In Phase 3 (P3) studies, tofacitinib demonstrated safety and efficacy…Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting
Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome
Background/Purpose: We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…Abstract Number: 1485 • 2014 ACR/ARHP Annual Meeting
Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study
Background/Purpose Active RA significantly impairs health-related quality of life (HRQoL) and physical function of patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in macrophage…Abstract Number: 1484 • 2014 ACR/ARHP Annual Meeting
Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
Background/Purpose: The Non-receptor tyrosine kinases, JAK3 and ITK are key regulators of cytokine pathways and are important clinically validated targets, which offer the potential for…Abstract Number: 1483 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase
Background/Purpose Baricitinib (bari), an oral JAK1/JAK2 signaling inhibitor, was evaluated in a blinded phase 2b study for 12 weeks as a treatment for rheumatoid arthritis…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 13
- Next Page »